Forte Biosciences
Tracked across 3 events · 19 articles · First seen Apr 08, 2026 · Last active Aug 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Forte Biosciences commenced and priced a public offering of its common stock to raise approximately $150 million for working capital and clinical development.
Apr 08, 2026 · 7 articles
Business
Impact: Forte is being acquired at a significant premium; its lead asset FB102 gains access to Argenx's development and commercial capabilities.
Jul 27, 2026 · 6 articles
Tech
Forte Biosciences, a clinical-stage biotechnology company, announced it will host an educational symposium at PAINWeek 2026 titled 'A New Era in Pain Therapeutics.' The symposium will showcase the company's neural reset strategy for its botanical…
Impact: Hosting the symposium and presenting its CY200 candidate and safety switch technologies, Ensysce aims to raise awareness and potentially advance its clinical development. The event is a promotional opportunity but does not alter its financial position.
Aug 20, 2026 · 6 articles
70
Forte Biosciences announced symposiumEnsysce Biosciences...
ERGEN INTELLIGENCE
Track Forte Biosciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard